Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CVS Health Corporation (NYSE: CVS) between May 3, 2023 and April 30, 2024, both dates inclusive (the “Class Period”), of the important September 10, 2024 lead plaintiff deadline.

ROSEN, A LEADING LAW FIRM, Encourages CVS Health Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CVS

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Investors Can Spearhead The Securities Fraud Lawsuit Of CVS Health Corporation With The Schall Law Firm

CVS Health, Walgreens and Herbalife are included in this Analyst Blog.

The Zacks Analyst Blog CVS Health, Walgreens and Herbalife

NEW YORK, NY / ACCESSWIRE / August 8, 2024 / If you suffered a loss on your CVS Health Corporation (NYSE:CVS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cvs-health-corporation-lawsuit-submission-form?prid=94676&wire=1 or contact Joseph E. Levi, Esq.

CVS Health Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 10, 2024 to Discuss Your Rights – CVS

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Investors Are Encouraged To Take The Lead In The CVS Health Corporation Securities Fraud Lawsuit With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 8, 2024 / If you suffered a loss on your CVS Health Corporation (NYSE:CVS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cvs-health-corporation-lawsuit-submission-form?prid=94654&wire=1 or contact Joseph E. Levi, Esq.

CVS Health Corporation Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - CVS

Wall Street analysts currently rate CVS stock as a solid BUY with a consensus weighted average rating of 3.75. Wall Street buy rating understated the risks of elevated Medicare Advantage utilization rates in my view. Judging by its Q2 results and forward guidance, the pressure from the MA program can persist longer than expected.

CVS Health Q2: Don't Fight Bad Economics

The near-term challenges for CVS Health (CVS) are no doubt worrisome. Yet, the company remains focused on its strategic moves, utilizing integrated healthcare models and technological advancements.

What is the Right Approach for CVS Health (CVS) Post Q2 Results?

NEW YORK , Aug. 8, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of CVS Health Corporation (NYSE: CVS). Shareholders who purchased shares of CVS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Class Action Filed Against CVS Health Corporation (CVS) - September 10, 2024 Deadline to Join - Contact The Gross Law Firm

CVS Health grew its revenues by 2.6% in the second quarter, crediting this year-over-year improvement in part to its growing number of digital customers, its offering of biosimilar prescriptions and its closure of underperforming stores.

CVS: Growing Digital Reach Contributes to Revenue Growth

LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE: CVS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

CVS Investors Are Invited To Take The Lead In The CVS Health Corporation Securities Fraud Case With The Schall Law Firm

In a Wednesday interview with CNBC's Jim Cramer, CVS CEO Karen Lynch said she is taking responsibility for the company's Aetna insurance business after some metrics over the most recent quarter missed expectations. "I'm taking direct ownership and am going to focus on the financial and operational execution of that business," she said.

CVS CEO says she's 'taking direct ownership' to fix Aetna insurance business

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CVS Health Corporation (NYSE: CVS) between May 3, 2023 and April 30, 2024, both dates inclusive (the “Class Period”), of the important September 10, 2024 lead plaintiff deadline.

ROSEN, LEADING INVESTOR COUNSEL, Encourages CVS Health Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CVS

CVS Health said on Wednesday that high demand for medical care among older adults hit second-quarter results, a trend that continued into July, causing it to slash its 2024 earnings forecast.

‘Frustrating quarter': CVS Health predicts medical costs will be higher in the second half of the year

CVS Health Corporation reported Q2 earnings earlier today, with revenues up nearly 2.6% year-on-year, but profits down year-on-year. CVS' health insurance business underperformed, leading to downgraded guidance for 2024 — the President of CVS Aetna division has paid the price, and been removed from his post. CVS' CEO Karen Lynch — a healthcare insurance veteran — will take back control of Aetna and its day-to-day running for now.

CVS Health Q2 Earnings: CEO's Swinging Axe May Have Ended The Bear Run

U.S. stocks turned lower toward the end of trading, with the Dow Jones index dipping more than 200 points on Wednesday.

Dow Tumbles Over 200 Points; CVS Health Cuts Profit Forecast

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of CVS Health Corporation (NYSE: CVS).

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 10, 2024 in CVS Health Corporation Lawsuit – CVS

CVS Health Corporation (NYSE:CVS ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Karen Lynch - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial Officer Prem Shah - Executive Vice President, Chief Pharmacy Officer David Joyner - Executive Vice President, CVS Health Larry McGrath - Senior Vice President, Investor Relations Conference Call Participants Lisa Gill - JP Morgan Justin Lake - Wolfe Research Stephen Baxter - Wells Fargo Ann Hynes - Mizuho Eric Percher - Nephron Research Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Kevin Caliendo - UBS Lance Wilkes - Bernstein Charles Rhyee - TD Cowen Brian Tanquilut - Jefferies Operator Good morning or good afternoon all and welcome to the CVS Health Q2 2024 earnings conference call. My name is Adam and I'll be your Operator today.

CVS Health (CVS) Q2 2024 Earnings Call Transcript

CVS Health said pressure in its benefits segment prompted another cut to its full-year forecast. Here's what you need to know.

CVS Health Stock Drops After Cutting Profit Forecast Again

CVS said Wednesday that it's launching a multi-year productivity initiative. It also cut its outlook for the year as its health care benefits segment continues to face pressure.

CVS cuts outlook, plans $2B cost-cutting effort

Although the revenue and EPS for CVS Health (CVS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, CVS Health (CVS) Q2 Earnings: A Look at Key Metrics

CVS Health (CVS) shares lost ground in early trading Wednesday after the pharmacy giant slashed its 2024 earnings guidance again amid increased medical costs and announced the departure of the head of its Aetna unit.

CVS Cuts Its Full-Year Profit Outlook, Again

CVS Health (CVS) delivers a year-over-year improvement in revenues, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.

CVS Health (CVS) Beats Q2 Earnings, Narrows '24 EPS Outlook

CVS Health (CVS) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of $1.74 per share. This compares to earnings of $2.21 per share a year ago.

CVS Health (CVS) Beats Q2 Earnings Estimates

Shares in CVS Health Corp (NYSE:CVS) were under pressure pre-market after it lowered full-year forecasts due to medical costs. The impact of the news was partially offset by a second-quarter earnings print that exceeded expectations.

News for CVS Health Stock (CVS)